Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
1204144-28-4
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C25H27N7O2
|
| gptkbp:hasSMILES |
C1COCCN1C2=CC=C(C=C2)NC(=O)CN3C=NC=NC3C4=CN=CC=C4
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD1208
|
| gptkbp:investigatedBy |
gptkb:acute_myeloid_leukemia
|
| gptkbp:IUPACName |
N-(4-(4-morpholinyl)phenyl)-2-(4-(pyridin-3-yl)pyrimidin-2-ylamino)acetamide
|
| gptkbp:mechanismOfAction |
PIM kinase inhibitor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
46209416 DB12098 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
PIM kinases
|
| gptkbp:bfsParent |
gptkb:PIM_1
|
| gptkbp:bfsLayer |
7
|